ADMA
NASDAQ · Biotechnology
Adma Biologics Inc
$9.90
-0.16 (-1.59%)
Financial Highlights (FY 2026)
Revenue
474.12M
Net Income
136.54M
Gross Margin
57.4%
Profit Margin
28.8%
Rev Growth
+49.0%
D/E Ratio
0.15
Revenue & Net Income
Margin Trends
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Gross Margin | 57.4% | 57.4% | 49.6% | 49.6% |
| Operating Margin | 36.9% | 33.2% | -9.0% | -9.9% |
| Profit Margin | 28.8% | 27.4% | -10.4% | -8.5% |
Income Statement
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Revenue | 474.12M | 318.12M | 922.90M | 1.03B |
| Gross Profit | 272.10M | 182.57M | 457.58M | 508.40M |
| Operating Income | 174.81M | 105.56M | -82,955,088 | -101,708,220 |
| Net Income | 136.54M | 82.45M | -95,808,796 | -87,264,834 |
| Gross Margin | 57.4% | 57.4% | 49.6% | 49.6% |
| Operating Margin | 36.9% | 33.2% | -9.0% | -9.9% |
| Profit Margin | 28.8% | 27.4% | -10.4% | -8.5% |
| Rev Growth | +49.0% | +49.0% | +20.1% | +10.2% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Total Debt | 147.89M | 147.89M | 1.56B | 1.50B |
| Total Equity | 978.75M | 978.75M | 2.42B | 2.53B |
| D/E Ratio | 0.15 | 0.15 | 0.64 | 0.59 |
Cash Flow
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| EBITDA | 174.96M | 111.52M | -107,012,515 | -125,992,506 |
| Free Cash Flow | — | — | -83,155,340 | -96,884,239 |